Background
==========

Complementary and alternative medicines (CAM) are now mainstream in the UK and the rest of Europe, as well as in North America and Australia \[[@B1]-[@B4]\]. Consumers of herbal products available over the counter need access to reliable and readily accessible information to ensure their safe and appropriate use. The written information people get when they buy herbal products is particularly important because, although research in this area is sparse, it has been shown that in the UK staff knowledge about the products sold in community pharmacies and health food shops can be lacking \[[@B5]\].

Research carried out for the UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) \[[@B1]\], found that many people believe that herbal products are safe because they are natural, confirming previous findings \[[@B6],[@B7]\], and that patients often refrain from telling their physicians if they are using an herbal product. Equally important is that few doctors ask patients about their use of CAM, including herbal products \[[@B8]\].

Many herbal products have adverse effects that are not acknowledged or known by their users, with about one-third being unaware of any possible risks \[[@B9]\]. In addition, most healthcare professionals believe that the public is poorly informed about herbal products \[[@B10]\]. A report by the MHRA \[[@B11]\] stated, *\'With typical western herbal medicine e.g. found in health food shops supermarkets etc the most frequent area of concern in the unlicensed sector is lack of systematic patient information\'*(p. 6).

The need for reliable information is one of four points highlighted in the World Health Organisation (WHO) Traditional Medicines Strategy of 2002 \[[@B12]\]. In addition, a WHO World Health Assembly resolution issued in 2003 urged member states to provide reliable information to consumers to promote proper use of CAM.

Key pieces of information about the safe use of herbal products that consumers need to know include (1) precautions, because many herbal products can be unsafe for use by people with some preexisting illnesses, for example, the use of Asian ginseng by people with diabetes; (2) interactions with other products, for example, the use of St John\'s wort affecting the efficacy of the contraceptive pill or warfarin; and (3) adverse effects, for example, allergic reactions associated with the use of ginkgo \[[@B13]\]. Without such information, it will be more difficult for the consumer to be able to make an informed choice whether to use CAM, with possible consequent adverse effects.

In some European countries, the use of herbal remedies is widespread and well established \[[@B14]\]. Other countries have a historical tradition of using herbal medicines, such as the UK \[[@B15]\], and in other European countries there are existing regulations for CAM (for example, Austria and Germany \[[@B3]\]). Until 2011 in the UK, there were three possible regulatory routes by which an herbal product could reach a consumer. The most common route was an unlicensed herbal remedy, which does not have to meet specific standards of safety and quality and is not required to be accompanied by safety information for the consumer \[[@B11]\]. To help the public make informed choices about the use of herbal products, a European Union (EU) directive was implemented in April 2011 after a seven-year transition period. The goal of this directive is to harmonise the regulation of traditional herbal medicine products across the EU and to establish a simplified licensing system \[[@B16]\]. It requires that all manufactured herbal products either gain a product licence of the type needed to manufacture \'conventional\' products or become registered as a \'traditional herbal medicinal product\'.

Licensed herbal medicines
-------------------------

Licensed herbal medicines hold a product licence, as do conventional medicines (that is, based on safety, quality and efficacy), and must be accompanied by comprehensive information for the patient regarding their safe use. This information comprises six categories: indications, precautions, how to use the product, side effects, how to store the product and regulatory information, all of which are usually provided on a leaflet inserted into the product package \[[@B17]\]. In addition, the leaflets have to be tested with lay people to ensure that they are clear and understandable \[[@B18]\]. However, it is widely recognised that, although there is some evidence of efficacy for some herbal medicines, evidence of reproducible efficacy in many cases is currently insufficient to meet regulatory standards. Hence a licence to sell these products cannot be obtained.

Registered traditional herbal medicine
--------------------------------------

The new category of Traditional Herbal Registration (THR) was created in April 2004 with a transition period of seven years \[[@B19]\]. As a result, in the UK, a \'simplified registration scheme\', the Traditional Herbal Medicines Registration Scheme, was introduced. In this scheme, herbal medicine products have been required to meet specific standards of safety and quality, have agreed-upon indications for use based on their traditional use and include information for the purchaser to promote the safe use of the product, which is provided to the consumer in the form of a leaflet similar to that required for licensed products \[[@B17]\]. The resulting deadline was 30 April 2011.

We found no previous studies on patient information supplied with herbal products available for purchase in the UK. Building on previous work describing consumer information provided with conventional medicines \[[@B20]\], we aimed to evaluate the information provided with a select set of common herbal products available for purchase in the UK. The objective was to ascertain whether the products contained the minimum information required to enable their safe use.

Methods
=======

Study design
------------

We conducted a cross-sectional survey involving content analysis of written information provided with five commonly used herbal products: St John\'s wort, garlic, ginkgo, Asian ginseng and echinacea. These herbal products were chosen because one or more of the following factors applied to each of them: evidence of interaction between herbal medicine and a prescribed medicine \[[@B21]\], a risk-benefit profile had been undertaken \[[@B22]\] and availability in retail outlets in local shopping areas. We chose to include single-ingredient products intended for oral use. We excluded products available as creams, liquids, oils, sprays, teas and tinctures.

Obtaining the products
----------------------

In the UK, herbal remedies are available in health food shops and mainstream outlets such as pharmacies and supermarkets \[[@B23],[@B24]\]. Hence we bought all of the oral use products containing one of the five herbal products from three types of retail establishment in one city. The sources were (1) two health food stores, Holland and Barrett (the largest UK retail chain in this sector), and an independent health food store associated with the National Association of Health Food Stores; (2) three pharmacies based in supermarkets (Tesco, Sainsbury\'s and Asda); and three large chain pharmacies (Boots, Superdrug and Lloyds Chemists).

Evaluation criteria
-------------------

We evaluated the information that accompanies each product for completeness and accuracy in the key safety areas of precautions, interactions and side effects. The assessment of the completeness and accuracy of the information was not straightforward. There is no single, recognised, authoritative source of information on herbal medicines. Reference texts for herbal medicines include Barnes *et al.*\[[@B25]\], the Natural Medicines Comprehensive Database \[[@B26]\], Mills and Bone \[[@B27]\], Blumenthal *et al.*\[[@B28]\], the European Medicines Agency \[[@B29]\] and the US National Center for Complementary and Alternative Medicine (NCCAM) \[[@B13]\].

However, no single text appears to be regarded as the gold standard. In addition, the evidence basis for some precautions, interactions and side effects is limited, and sometimes there is no consensus regarding what these are and their level of significance.

As this study was a general exercise designed to broadly determine the appropriateness of information provided with herbal medicine products, we chose to base it on data contained in a free access resource containing the most important and widely accepted safety information. The Community Herbal Monographs published online by the European Medicines Agency \[[@B29]\] did not cover all five herbal medicine preparations. However, they are all covered by the monographs produced by the NCCAM \[[@B13]\], which were therefore chosen. NCCAM is part of the US National Institutes of Health, and one of its roles is \"disseminating authoritative information to the public and professionals\". The monographs are short (two pages) and contain only the most important information and warnings.

Each monograph was analysed for content to identify information related to precautions, interactions and side effects. Analysis of the NCCAM monographs yielded 16 points of information for St John\'s wort, 11 for ginkgo, 8 for garlic and for Asian ginseng, and 6 for echinacea (Table [1](#T1){ref-type="table"}).

###### 

Key safety issues^a^

  St John\'s wort                                  Ginkgo                                                 Asian ginseng                                                                                                                                                     Garlic                                                                  Echinacea
  ------------------------------------------------ ------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------
  **Precautions**                                                                                                                                                                                                                                                                                                                                   
  Sensitivity to sunlight                          Increased bleeding risk                                People with diabetes should use extra caution, especially if using medicines to lower blood sugar or taking other herbs \... also thought to lower blood sugar.   Can thin the blood                                                      Allergy to related plants in daisy family
                                                   Bleeding disorders                                                                                                                                                                                                       Use with caution if planning to have surgery or dental work.            People with asthma or atopy may be more likely to have an allergic reaction.
                                                   Scheduled surgery or dental procedures                                                                                                                                                                                   Use with caution if you have a bleeding disorder.                       
  **Interactions**                                                                                                                                                                                                                                                                                                                                  
  Antidepressants                                  Anticoagulant drugs                                                                                                                                                                                                      Interferes with effectiveness of saquinavir, a drug used to treat HIV   
  Oral contraceptives                                                                                                                                                                                                                                                                                                                               
  Digoxin                                                                                                                                                                                                                                                                                                                                           
  Indinavir and possibly other HIV medications                                                                                                                                                                                                                                                                                                      
  Irinotecan and possibly other anticancer drugs                                                                                                                                                                                                                                                                                                    
  Seizure control drugs                                                                                                                                                                                                                                                                                                                             
  Warfarin and related anticoagulants                                                                                                                                                                                                                                                                                                               
  Cyclosporine                                                                                                                                                                                                                                                                                                                                      
  **Side effects**                                                                                                                                                                                                                                                                                                                                  
  Anxiety                                          Headache                                               Headache                                                                                                                                                          Breath and body odour                                                   Allergic reactions including rashes
  Dry mouth                                        Nausea                                                 Sleep problems                                                                                                                                                    Heartburn                                                               Increased asthma
  Dizziness                                        Gastrointestinal upset                                 Gastrointestinal problems                                                                                                                                         Upset stomach                                                           Anaphylaxis
  Gastrointestinal symptoms                        Diarrhoea                                              Allergic reactions                                                                                                                                                Allergic reactions                                                      Gastrointestinal side effects
  Fatigue                                          Dizziness                                              Breast tenderness                                                                                                                                                                                                                         
  Headache                                         Allergic skin reactions                                Menstrual irregularities                                                                                                                                                                                                                  
  Sexual dysfunction                               More severe allergic reactions occasionally reported   High blood pressure                                                                                                                                                                                                                       

^a^As identified in the NCCAM Herbs at a Glance monographs \[[@B13]\].

We then performed a structured content analysis of the information supplied with each of the purchased products on the outer and inner packaging and any leaflet contained within the package. Each piece of information was marked as being \'present and accurate\' or \'inaccurate or absent\'. We marked information as correct if it broadly described the information correctly. For example, where the interacting medicine was digoxin, a leaflet description of \'some products for heart disease\' was deemed to be accurate.

Data extraction and quality assurance
-------------------------------------

All of the textual information on each product container (and leaflet, if present) was photocopied so that we could create a master copy of the information supplied with each product. This information was then examined by one researcher (RD), and the presence or absence of each point of information was entered into a Microsoft Excel database (Microsoft, Redmond, WA, USA). The nine products supplied with an information leaflet were also assessed by a second researcher (DKR). A check of a randomly selected 10% of the products with information on the package only was independently conducted (DKR). Any differences were resolved by discussion to reach consensus.

Results
=======

Nature of the products
----------------------

We found 68 products sold by 8 different retailers which met the inclusion criteria: garlic, 21; St John\'s wort, 15; echinacea, 13; ginkgo, 12; and Asian ginseng, 7.

Regulatory category
-------------------

The great majority (93%) of products were unlicensed. Of these, 48 stated that they were food supplements. The rest had no classification stated, so the actual product classification could only be determined on a case-by-case basis by the regulator. It is likely that a number of products were supplied as unlicensed herbal medicines under the Medicines Act 1968. The remaining five products (7%) had either a product licence or THR. The breakdown of the herbal products was as follows: unlicensed, 63; THR, 2; and licensed product, 3.

Information provided
--------------------

Among the 68 products, 59 (87%) of the manufacturers provided information on the package and/or on the label only, and nine also provided a leaflet package insert. The latter nine products were St John\'s wort (4 of 15), echinacea (3 of 13) and garlic (2 of 21). Each of the products with a product licence (*n*= 3) or THR (*n*= 2) had a leaflet, but the remainder were unlicensed. One of these leaflets mostly contained information promoting other products. However, as the leaflet contained some brief information on the herbal medicine concerned, it was included.

Key points of safety information
--------------------------------

Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"} list each product by the number allocated to it in this study (\'study number\'), its legal category (where stated on the product), whether a leaflet was supplied with the product and the number of safety messages included (sub-divided into \'Precautions\', \'Interactions\' and \'Side effects\'). The two products with THR both contained 14 of 16 of the points of information. Table [7](#T7){ref-type="table"} lists the number of products which contained none of the points of information.

###### 

St John\'s wort^a^

  Study number           1    2    3    4     67   70   72   75   30   31    32    41   48    58   61
  ---------------------- ---- ---- ---- ----- ---- ---- ---- ---- ---- ----- ----- ---- ----- ---- ----
  Where bought           HF   HF   HF   HF    HF   HF   HF   HF   Ph   Ph    Ph    Ph   Ph    SM   SM
  Legal category         U    U    U    THR   U    U    U    U    U    THR   U     U    U     U    U
  Leaflet supplied?      No   No   No   Yes   No   No   No   No   No   Yes   Yes   No   Yes   No   No
  Precautions, *n*= 1    1    0    1    1     0    0    0    1    1    1     1     0    1     0    1
  Interactions, *n*= 8   0    0    0    8     0    0    0    0    7    8     7     0    7     0    0
  Side effects, *n*= 7   0    0    0    5     0    0    0    0    0    5     0     0    0     0    0

^a^HF = health food shop, Ph = pharmacy, SM = supermarket, U = unlicensed, THR = traditional herbal registration, PL = product licence. Each product is listed by study number, where St John\'s wort was bought, legal category, whether a leaflet was supplied and the number of safety messages (under \'Precautions\', \'Interactions\' and \'Side effects\').

###### 

Ginkgo^a^

  Study number           5    6    7    8    73   33   34   35   36   42   56   64
  ---------------------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----
  Where bought           HF   HF   HF   HF   HF   Ph   Ph   Ph   Ph   Ph   SM   SM
  Legal category         U    U    U    U    U    U    U    U    U    U    U    U
  Leaflet supplied?      No   No   No   No   No   No   No   No   No   No   No   No
  Precautions, *n*= 4    0    0    0    0    0    0    0    0    0    0    0    0
  Side effects, *n*= 7   0    0    0    0    0    0    0    0    0    0    0    0

^a^HF = health food shop, Ph = pharmacy, SM = supermarket, U = unlicensed.

###### 

Asian ginseng^a^

  Study number           9    10   12   15   76   55   60
  ---------------------- ---- ---- ---- ---- ---- ---- ----
  Where bought           HF   HF   HF   HF   HF   SM   SM
  Legal category         U    U    U    U    U    U    U
  Leaflet supplied?      No   No   No   No   No   No   No
  Precautions, *n*= 1    0    0    1    0    0    0    0
  Side effects, *n*= 7   0    0    0    0    0    0    0

^a^HF = health food shop, SM = supermarket, U = unlicensed.

###### 

Garlic^a^

  Study number           19   20   21   22   23    24   25   26   69   71   74   43   49   50   52   53   54    45   46   59   62
  ---------------------- ---- ---- ---- ---- ----- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----- ---- ---- ---- ----
  Where bought           HF   HF   HF   HF   HF    HF   HF   HF   HF   HF   HF   Ph   Ph   Ph   Ph   Ph   Ph    SM   SM   SM   SM
  Legal category         U    U    U    U    U     U    U    U    U    U    U    U    U    U    U    U    U     U    U    U    U
  Leaflet supplied?      No   No   No   No   Yes   No   No   No   No   No   No   No   No   No   No   No   Yes   No   No   No   No
  Precautions, *n*= 4    0    0    0    0    0     0    0    0    0    0    0    0    0    1    0    0    0     0    0    0    0
  Side effects, *n*= 4   0    0    0    0    0     0    0    0    0    0    0    0    0    0    0    0    0     0    0    0    0

^a^HF = health food shop, Ph = pharmacy, SM = supermarket, U = unlicensed.

###### 

Echinacea

  Study number           66   68   77   16    17   37    38   39   40   47    57   44   63
  ---------------------- ---- ---- ---- ----- ---- ----- ---- ---- ---- ----- ---- ---- ----
  Bought from            HF   HF   HF   HF    HF   Ph    Ph   Ph   Ph   Ph    SM   SM   SM
  Legal category         U    U    U    PL    U    PL    U    U    U    PL    U    U    U
  Leaflet supplied?      No   No   No   Yes   No   Yes   No   No   No   Yes   No   No   No
  Precautions, *n*= 2    0    0    1    0     1    0     0    0    0    0     0    0    0
  Side effects, *n*= 4   0    0    0    1     0    1     0    0    0    0     0    0    0

^a^HF = health food shop, Ph = pharmacy, SM = supermarket, U = unlicensed, PL = product licence.

###### 

Presence or absence of information points for each category of herbal product

  Herbal product                 Some points of information   No points of information
  ------------------------------ ---------------------------- --------------------------
  St John\'s wort, *n*= 15 (%)   11 (73%)                     4 (27%)
  Ginkgo, *n*= 12 (%)            0 (0%)                       12 (100%)
  Asian ginseng, *n*= 7 (%)      1 (14%)                      6 (86%)
  Garlic, *n*= 21 (%)            1 (5%)                       20 (95%)
  Echinacea, *n*= 13 (%)         4 (31%)                      9 (69%)
  Total, *n*= 68 (%)             17 (25%)                     51 (75%)

Discussion
==========

The public should be able to expect full disclosure of key safety information when they purchase products herbal medicines over the counter \[[@B16]\]. This study has shown that, among five herbal products commonly purchased over the counter in the UK, most contained little or no information regarding what to check for in order to avoid harm before using the product. Three-quarters of the preparations contained no safety information, and only three contained most or all of the points of information studied. For St John\'s wort, which has generated the most publicity regarding safe use, two-thirds of the preparations failed to mention any of the possible interactions with conventional medicines such as the oral contraceptive or warfarin. This is consistent with the findings of Clauson *et al.*\[[@B30]\] in the USA, where the manufacturers of the vast majority of St John\'s wort preparations failed to adequately address clinically relevant safety issues.

This study provides evidence supporting the need to strengthen regulation of herbal medicines in the EU \[[@B23]\]. Our results show that where a product (here, St John\'s wort) was registered as a THR, over 85% of the safety information studied was included in the information for the consumer. That this figure was not 100% reflects, as stated above, the lack of consensus on the safety information associated with individual herbal medicines. The information provided with these THR products reflects the MHRA\'s assessment and is consistent with data in the European Medicines Agency\'s Community Herbal Monographs \[[@B29]\].

The number of THR remains small; in this study, the majority of products were not registered, and by April 2011 the MHRA had received 211 applications for THR, among which 104 applications had so far been granted and the remainder were under assessment (R Woodfield, personal communication).

The introduction of the THR regulations in the UK in April 2011 does not mean, however, that the issues highlighted by this research will be fully resolved. First, although most products containing either St John\'s wort or echinacea are likely to be classified as medicinal products (and hence their manufacturers will be required to provide comprehensive information to the patient), the position of garlic, ginkgo and ginseng is less clear. Those products which make no claims to treat or prevent disease will fall outside the regulatory remit (R Woodfield, personal communication). Second, although unregulated products should no longer be entering the supply chain, stock already legally held by retailers can continue to be sold, although this will be a time-limited issue. Finally, there is a continuing likelihood of internet availability of products from manufacturers and suppliers in countries outside the jurisdiction of the MHRA.

Printing herbal medicine product information for the consumer on the outside of the package is important to enabling its safe use. Cramer *et al.*\[[@B5]\] point to a continued lack of knowledge among pharmacy staff about herbal products available in pharmacies. Furthermore, although research evidence from health food shops was limited, the advice offered there also appears to be varied and inconsistent. Importantly, Cramer and colleagues found that a significant majority of people who buy herbal products need help in selecting an appropriate product. Others have recognised that pharmacists lack training and knowledge regarding herbal remedies \[[@B31]\]. Most pharmacy customers in an Australian study thought pharmacists should provide safety information about herbal products \[[@B4]\], and in Canada, most consumers and pharmacists thought pharmacists should be knowledgeable about natural health products and able to manage possible drug interactions \[[@B32]\].

In addition to the general need for the public to be educated about the safe use of herbal products and know where to find good information about them, there is a related issue about patients telling their healthcare providers about their herbal product use. There appears to be a general reluctance of patients to tell this to their physicians, with one UK study finding that a large majority did not tell their general practitioners about their use of herbal products \[[@B33]\]. Consumers should be encouraged to tell their healthcare practitioners about any use of herbal products, and practitioners should consider initiating such discussions \[[@B34]\]. This does not, however, take away the necessity for accurate and complete written information about precautions, interactions and side effects to be provided to consumers when they buy herbal products.

The most commonly discussed safety problems associated with the use of herbal products relate to interactions with medicine prescribed by a conventional biomedical practitioner. We know that the use of over-the-counter herbal products concomitantly with conventional medicines is widespread and that there are numerous possible interactions \[[@B21]\]. In a study of cardiology patients, among the herbal products singled out, all five included in the present study were described as being especially dangerous in elderly patients \[[@B35]\]. A UK survey of health professionals found that 86% think the public is poorly informed about herbal products, with the main reason for concern being potential interactions with traditional medicines \[[@B10]\].

Apart from the information provided on or in the herbal product package, what other sources do people use to find out about herbal products? Cramer *et al.*\[[@B5]\] found that pharmacy customers accessed information from CAM practitioners, friends and family, books, newspapers, magazines and the internet. However, reliable and readily accessible information sources on herbal medicines are limited \[[@B36]\]. A survey focussing on ginseng, ginkgo and St John\'s wort found that among 150 websites, 25% contained statements that could cause harm to users of these herbal products and 97% had omitted information \[[@B37]\].

Conclusions
===========

It is clear that consumers are entitled to better information with the CAM that they buy, so that they are aware of any safety issues and to enable them to make informed decisions \[[@B7]\]. Just as for conventional medicines, this is important for herbal products as well, because harm to the consumer is possible when such information is not available. The 2011 EU legislation will ensure that such information is available for many products, but products not classified as medicinal products will escape the net of regulation. Also, existing stock will continue to be legally available for a period and internet purchases from sources outside the EU will not be covered. This means that consumers need to be advised where and how to purchase herbal products so that the necessary information for safe use will be available to them. They should look for products registered as THR and seek outlets where staff might be anticipated to have knowledge of and training in the safe use of herbal products. In addition, there should be ongoing monitoring of the written information supplied with these products to encourage improvements in this important safety issue.
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